Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von willebrand factor string formation under flow in a free-thiol-dependent manner

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 2, 2014, Pages 397-407

  Bao, Jialing ^a   Xiao, Juan ^a,c   Mao, Yingying ^a   Zheng, X Long ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ADAMTS13; animal model; arterial thrombosis; thrombotic thrombocytopenic purpura; von Willeband factor

Indexed keywords

ADAMTS13; ANIMAL MODEL; ARTERIAL THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBAND FACTOR;

ADAM PROTEINS; ANIMALS; BLOOD PLATELETS; CHO CELLS; COLLAGEN; CRICETINAE; CRICETULUS; HEK293 CELLS; HUMANS; METALLOENDOPEPTIDASES; MICE; MICE, KNOCKOUT; MICROFLUIDIC ANALYTICAL TECHNIQUES; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; STRESS, MECHANICAL; SULFHYDRYL COMPOUNDS; THROMBOSIS; TIME FACTORS; TRANSFECTION; VON WILLEBRAND FACTOR;

EID: 84895065183     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302547     Document Type: Article

References (30)

1. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. J Cell Biol. 1984;99:2123-2130
2. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, López JA. ADAMTS-13rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-4039
3. Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, López JA, Cruz MA. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633-29639
4. Huang J, Motto DG, Bundle DR, Sadler JE. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood. 2010;116:3653-3659
5. Jin SY, Skipwith CG, Shang D, Zheng XL. von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size. J Thromb Haemost. 2009;7:1749-1752
6. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009;114:1666-1674
7. Nolasco L, Nolasco J, Feng S, Afshar-Kharghan V, Moake J. Human complement factor H is a reductase for large soluble von Willebrand factor multimers-brief report. Arterioscler Thromb Vasc Biol. 2013;33:2524-2528
8. Moake JL. Thrombotic thrombocytopenic purpura: The systemic clumping"plague". Annu Rev Med. 2002;53:75-88
9. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 2008;3:249-277
10. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem. 2005;280:29428-29434
11. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A. 2006;103:19099-19104
12. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood. 2008;112:1713-1719
13. Soejima K, Matsumoto M, Kokame K, Yagi H, Ishizashi H, Maeda H, Nozaki C, Miyata T, Fujimura Y, Nakagaki T. ADAMTS-13 cysteine-rich/ spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003;102:3232-3237
14. Tao Z, Wang Y, Choi H, Bernardo A, Nishio K, Sadler JE, López JA, Dong JF. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood. 2005;106:141-143
15. Xiao J, Jin SY, Xue J, Sorvillo N, Voorberg J, Zheng XL. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2011;31:2261-2269
16. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.J Biol Chem. 2003;278:30136-30141
17. Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A. 2009;106:19274-19279
18. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood. 2010;115:2300-2310
19. Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 2010;115:1640-1649
20. Xiang Y, de Groot R, Crawley JT, Lane DA. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci U S A. 2011;108:11602-11607
21. Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2005;93:267-274
22. Luken BM, Kaijen PH, Turenhout EA, Kremer Hovinga JA, van Mourik JA, Fijnheer R, Voorberg J. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4:2355-2364
23. Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, van Mourik JA, Fijnheer R, Voorberg J. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost. 2006;96:295-301
24. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, Bennett CL, Kwaan HC. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010;95:1555-1562
25. Yeh HC, Zhou Z, Choi H, Tekeoglu S, May W 3rd, Wang C, Turner N, Scheiflinger F, Moake JL, Dong JF. Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost. 2010;8:2778-2788
26. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, Tomiyama Y, Miyata T. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006;107:3161-3166
27. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203:767-776
28. Niiya M, Endo M, Shang D, Zoltick PW, Muvarak NE, Cao W, Jin SY, Skipwith CG, Motto DG, Flake AW, Zheng XL. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther. 2009;17:34-41
29. Varadi K, Rottensteiner H, Vejda S, Weber A, Muchitsch EM, Turecek PL, Ehrlich HJ, Scheiflinger F, Schwarz HP. Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost. 2009;7:1134-1142
30. Fuchs B, Budde U, Schulz A, Kessler CM, Fisseau C, Kannicht C. Flow-based measurements of von Willebrand factor (VWF) function: Binding to collagen and platelet adhesion under physiological shear rate. Thromb Res. 2010;125:239-245